In a Phase 2 trial, DR10624 — a first-of-its-kind agent that targets FGF21, glucagon, and GLP-1 pathways — significantly lowered triglycerides and improved liver health markers. Such multi-receptor drugs could reshape treatment of metabolic causes of liver disease.
